BofA raised the firm’s price target on Krystal Biotech (KRYS) to $255 from $182 and keeps a Buy rating on the shares. The firm, which continues to like Vyjuvek, Krystal’s drug treating the rare skin condition dystrophic epidermolysis bullosa, also adjusts its pipeline and platform contribution estimates to add standalone revenue builds for KB801 and KB803 as it believes near-term pipeline data could be “value unlocking.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech gets FDA platform technology designation to HSV-1 viral vector
- Krystal Biotech’s Growth Potential Bolstered by FDA Approval and Promising Pipeline Developments
- Buy Rating for Krystal Biotech Driven by Vyjuvek’s Expanded Label and Market Potential
- Krystal Biotech announces FDA approval of update VYJUVEK label
- 3 ‘Outperform’ Healthcare Stocks, According to AI Analyst, 9/10/25